A Phase II Study of BAY 43-9006 [sorafenib] in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis)
Phase of Trial: Phase II
Latest Information Update: 29 Jul 2018
At a glance
- Drugs Sorafenib (Primary)
- Indications Bladder cancer; Pelvic cancer; Urogenital cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 11 Jul 2012 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 11 Jul 2012 Additional lead trial centre added as reported by ClinicalTrials.gov record.